Table 1

Characteristics of patients in the control group compared with treatment group and its two subgroups

CharacteristicsControl group n=76
n (%)
Treatment groups n=104 n (%)p Values
Total treatment group n=104AIC treatment subgroup n=75Non-AIC treatment subgroup n=29
Age mean±SD57.3±13.456.4±12.957.01±13.554.7±11.2p1=0.64
p2=0.41
Language
Hebrew
36 (47.4%)72 (69.2%)50 (66.7%)22 (75.9%)p1=0.004
p2=0.48
Country of birth
Israeli-born
42 (55.3%)62 (62.0%)46 (64.8%)16 (55.2%)p1=0.43
p2=0.37
Residence
Haifa and suburbs (vs periphery)
43 (56.6%)74 (71.2%)54 (72%)20 (69%)p1=0.057
p2=0.81
Cancer site: breast
(vs gynaecological cancers)
62 (81.6%)69 (66.9%)48 (64.0%)21 (72.4%)p1=0.04
p2=0.35
Cancer recurrence
Yes
23 (30%)29 (27.9%)20 (26.7%09 (31.0%)p1=0.74
p2=0.64
Evidence of metastasis
Yes
31 (40.8%037 (35.6%)27 (36.0%010 (34.5%0p1=0.53
p2=1.00
Oncology treatment setting
Adjuvant/neoadjuvant (vs palliative)
46 (61.3%)71 (68.3%)51 (68%)20 (69%)p1=0.34
p2=1.00
Education
High school and academic
47 (61.8%)88 (86.3%)65 (87.8%)23 (82.1%)p1=0.0003
p2=0.52
Occupation
Unemployed
36 (47.4%)34 (33.0%)21 (28.3%)13 (44.8%)p1=0.06
p2=0.16
Income
Average and below
65 (91.5%)79 (77.5%)55 (74.3%)24 (85.7%)p1=0.02
p2=0.29
Religiosity
Secular
33 (43.4%051 (50.5%)37 (50.7%)14 (50.0%)p1=0.36
p2=1.00
Religion
Jewish
54 (71.1%)82 (79.6%)58 (77.3%)24 (85.7%)p1=0.22
p2=0.42
Prior CM use, non-cancer-related:
Yes
35 (46.1%)65 (62.5%)51 (68.0%)14 (48.3%)p1=0.034
p2=0.074
Cancer-related CM use
Yes
8 (10.5%)63 (60.6%)52 (69.3%)11 (37.9%)p1<0.0001
p2=0.007
There is a connection between body and soul,* mean±SD5.57±1.756.30±1.316.31±1.266.27±15p1=0.021
p2=0.91
CM perceived effectiveness,* mean±SD5.04±2.055.64±1.315.90±1.184.73±1.33p1=0.10
p2=0.002
CM perceived risk,* mean±SD2.27±1.931.55±1.141.52±1.081.69±1.44p1=0.038
p2=0.63
  • p1=total treatment versus control; p2=AIC versus non-AIC.

  • *Data based on a Likert scale scored from 1 (very slightly agree) to 7 (agree very much).

  • AIC, adherence to integrative care; CM, complementary medicine.